MedTrace Logo

Study Evaluating Pharmacovigilance Of Refacto AF

NCT00895037 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2018-07-17

Study results available
· View outcomes & findings →

Summary

The purpose of this observational study is to describe the incidence of adverse events among patients treated with Refacto AF in usual health care settings in Germany and Austria.

Conditions

Interventions

DRUG

ReFacto AF (Moroctocog alfa)

Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-17
Primary Completion
2016-10-19
Completion
2016-10-19

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00895037 on ClinicalTrials.gov